Media
Home
Media
- Press
Minoryx presents positive interim results from NEXUS registration study for leriglitazone targeting pediatric ALD patients with cerebral adrenoleukodystrophy (cALD)Initial evidence of disease stabilization was demonstrated for all patients ...25/04/2023
The Lancet Neurology publishes results from Minoryx Therapeutics Phase 2/3 ADVANCE clinical trial of leriglitazone in X-linked AdrenoleukodystrophyLeriglitazone was well tolerated, and significant benefit was shown through ...20/01/2023
Leriglitazone’s clinical proof of concept data in Friedreich’s Ataxia published in Neurology GeneticsPublished data highlights therapeutic potential to treat patients with this ...29/11/2022Read more
- Events
Events in 2023
Events in 2022Events in 2021Events in 2020Events in 201911 Nov 2019 - 13 Nov 2019World Orphan Drug CongressBARCELONA11 Nov 2019 - 13 Nov 2019BIO-Europe 2019HAMBURG
